NIJMEGEN, the Netherlands--(BUSINESS WIRE)--Synthon today announced that the company's glatiramer acetate met the main endpoint of a late-stage study in patients with relapsing remitting multiple ...

BC Partners to Acquire Synthon International Holding B.V., a Global Market Leader in the Development of Complex Generics London, 2nd July 2019 – Funds advised by BC Partners (“BC Partners”), a leading ...

AHMEDABAD, India and NIJMEGEN, Netherlands, Sept. 4, 2025 /PRNewswire/ -- Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, today ...

NIJMEGEN, the Netherlands--(BUSINESS WIRE)--Synthon today announced that it has successfully concluded the decentralized procedures for glatiramer acetate, a therapeutically equivalent version of the ...

NIJMEGEN, The Netherlands--(BUSINESS WIRE)--The Supervisory Board of Synthon BV, an international, science-centered pharmaceutical company specialized in developing and manufacturing high-quality ...

Generic drug company Synthon Pharmaceuticals has received tentative U.S. Food and Drug Administration approval on its application to make a version of UCB‘s (EBR:UCB) allergy medicine Xyzal.

BC Partners will retain a minority stake in Synthon BC Partners acquired a majority stake in Synthon in 2019 The transaction is expected to close in the second quarter of 2025 BC Partners has agreed ...

SYD985 is a HER2-targeting ADC based on trastuzumab and Synthon's proprietary cleavable linker-duocarmycin (vc--DUBA) payload. Data support the potential of SYD985 to address the high unmet medical ...

NEW YORK & NIJMEGEN, Netherlands--(BUSINESS WIRE)--Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today announced they ...

All in vitro and in vivo studies conducted so far showed biosimilar behavior of Synthon’s trastuzumab in comparison with the reference product, Herceptin ® . The outcome of the phase I clinical trial ...